

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com

October 15, 2018

Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai – 400 001

Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039

2212203112212203

National Stock Exchange of India Ltd. "Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/

26598238

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on "Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market".


This is for your information.

With regards,

Encl: As above

CC:- New York

Press Release



DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

CONTACT	
INVESTOR RELATIONS	MEDIA RELATIONS
SAUNAK SAVLA saunaks@ drreddys.com (Ph: +91-40-49002135)	CALVIN PRINTER calyinprinter@ drreddys.com (Ph: +91-40- 49002121)

Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

Hyderabad, India, October 15, 2018

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. October 15, 2018— Dr. Reddy's Laboratories Ltd ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). The Company is working towards launching the product.

The Aggrenox brand and generic had U.S. sales of approximately \$183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.

Aggrenox is a registered trademark of Boehringer Ingelheim.

*IMS National Sales Perspective: Retail and Non-Retail MAT August 2018 RDY-1018-218

About Dr. Reddy's: Dr. Raddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietar Products - Dr. Raddy's of ers a port olio of products and ser ices including APIs, custom pharmaceutical ser ices, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.dreddys.com

Disclaimer: This press release may include statements of future expectations and other for ard-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncer ainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are for ard-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify for ard-looking statements. Actual results, per ormance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as per ormance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mor ality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.